Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.60 |
| ▸ | APEX1 | P27695 | 1/20 | 0.60 |
| ▸ | GLA | P06280 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.54 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.54 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.54 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.54 |
| ▸ | METAP2 | P50579 | 2/20 | 0.53 |
| ▸ | MPO | P05164 | 1/20 | 0.50 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.49 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL15054390 | 0.98 | APEX1 (0.58) | KDM4EAPEX1GLATDP1MEN1 | |
| Hydrochloric Acid SCHEMBL143713 | 0.98 | APEX1 (0.58) | KDM4EAPEX1GLATDP1MEN1 | |
| SCHEMBL16632333 | 0.86 | ACLY (0.54) | KDM4EAPEX1GLATDP1AKR1C3 | |
| Hydrochloric Acid SCHEMBL145407 | 0.85 | ACLY (0.53) | KDM4EAPEX1GLATDP1MEN1 | |
| SCHEMBL28361711 | 0.84 | APEX1 (0.60) | KDM4EAPEX1GLATDP1MEN1 | |
| SCHEMBL7544693 | 0.83 | KDM4E (0.59) | KDM4EAPEX1GLATDP1MEN1 | |
| SCHEMBL1323012 | 0.82 | APEX1 (0.58) | KDM4EAPEX1GLATDP1MEN1 | |
| SCHEMBL111313 | 0.79 | ALDH1A1 (0.76) | KDM4EAPEX1GLATDP1MEN1 | |
| SCHEMBL6036030 | 0.79 | MEN1 (0.57) | KDM4EAPEX1GLATDP1MEN1 | |
| SCHEMBL16248148 | 0.79 | APEX1 (0.55) | KDM4EAPEX1GLATDP1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190152979-A1 | SUBSTITUTED PYRAZOLOQUINAZOLINONES AND PYRROLOQUINAZOLINONES AS ALLOSTERIC MODULATORS OF GROUP II METABOTROPIC GLUTAMATE RECEPTORS | DOMAIN THERAPEUTICS (FR) | 2019-05-23 | — | — | US | disclosed |
| US-10221179-B2 | Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors | DOMAIN THERAPEUTICS (FR) | 2019-03-05 | — | — | US | disclosed |
| US-10196387-B2 | Carbazole compounds useful as bromodomain inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-02-05 | — | — | US | disclosed |
| EP-2961747-B1 | CARBAZOLE COMPOUNDS USEFUL AS BROMODOMAIN INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-11-15 | — | — | EP | disclosed |
| EP-2961747-B1 | CARBAZOLE COMPOUNDS USEFUL AS BROMODOMAIN INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-11-15 | — | — | EP | disclosed |
| US-20170305913-A1 | SUBSTITUTED PYRAZOLOQUINAZOLINONES AND PYRROLOQUINAZOLINONES AS ALLOSTERIC MODULATORS OF GROUP II METABOTROPIC GLUTAMATE RECEPTORS | DOMAIN THERAPEUTICS (FR) | 2017-10-26 | — | — | US | disclosed |
| EP-3197897-A1 | SUBSTITUTED PYRAZOLOQUINAZOLINONES AND PYRROLOQUINAZOLINONES AS ALLOSTERIC MODULATORS OF GROUP IIMETABOTROPIC GLUTAMATE RECEPTORS | Domain Therapeutics (FR) | 2017-08-02 | — | — | EP | disclosed |
| US-20170152248-A1 | CARBAZOLE COMPOUNDS USEFUL AS BROMODOMAIN INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-06-01 | — | — | US | disclosed |
| WO-2016046404-A1 | SUBSTITUTED PYRAZOLOQUINAZOLINONES AND PYRROLOQUINAZOLINONES AS ALLOSTERIC MODULATORS OF GROUP IIMETABOTROPIC GLUTAMATE RECEPTORS | DOMAIN THERAPEUTICS (FR) | 2016-03-31 | — | — | WO | disclosed |
| EP-3000814-A1 | Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors | Domain Therapeutics (FR) | 2016-03-30 | — | — | EP | disclosed |
| US-20050004126-A1 | Method of determining potential allosterically-binding matrix metalloproteinase inhibitors | ANDRIANJARA CHARLES (FR) | 2005-01-06 | — | — | US | disclosed |
| US-20040063673-A1 | Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors | JOHNSON ADAM RICHARD (US) | 2004-04-01 | — | — | US | disclosed |
| WO-2004014384-A2 | CYCLIC COMPOUNDS CONTAINING ZINC BINDING GROUPS AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
| WO-2004014384-A2 | CYCLIC COMPOUNDS CONTAINING ZINC BINDING GROUPS AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
| EP-1362048-A1 | TRIAZOLO COMPOUNDS AS MMP INHIBITORS | Warner-Lambert Company LLC (US) | 2003-11-19 | — | — | EP | disclosed |
| EP-1361873-A2 | MATRIX METALLOPROTEINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2003-11-19 | — | — | EP | disclosed |
| US-20030078276-A1 | Matrix metalloproteinase inhibitors | ANDRIANJARA CHARLES (FR) | 2003-04-24 | — | — | US | disclosed |
| US-20020151558-A1 | Triazolo compounds as MMP inhibitors | ANDRIANJARA CHARLES (FR) | 2002-10-17 | — | — | US | disclosed |
| WO-2002064080-A2 | MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LCC (US) | 2002-08-22 | — | — | WO | disclosed |
| WO-2002064595-A1 | TRIAZOLO COMPOUNDS AS MMP INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10196387-B2 | Carbazole compounds useful as bromodomain inhibitors | BRD3, BRD4, BRPF3 | KDM4E 975/4885APEX1 1025/4885GLA 2943/4885 |
| US-10221179-B2 | Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors | GRM1, GRM2, GRIN1 | KDM4E 2164/4885APEX1 3713/4885GLA 4658/4885 |
| US-20050004126-A1 | Method of determining potential allosterically-binding matrix metalloproteinase inhibitors | MMP13, MMP12, MMP25 | KDM4E 2484/4885APEX1 3150/4885GLA 1275/4885 |
| US-20030078276-A1 | Matrix metalloproteinase inhibitors | MMP13, MMP25, MMP12 | KDM4E 2733/4885APEX1 3252/4885GLA 1467/4885 |
| US-20170305913-A1 | SUBSTITUTED PYRAZOLOQUINAZOLINONES AND PYRROLOQUINAZOLINONES AS ALLOSTERIC MODULATORS OF GROUP II METABOTROPIC GLUTAMATE RECEPTORS | GRM1, GRM2, GRIN1 | KDM4E 2164/4885APEX1 3713/4885GLA 4658/4885 |
| US-20040063673-A1 | Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors | MMP13, MMP1, MMP11 | KDM4E 2155/4885APEX1 453/4885GLA 296/4885 |
| US-20170152248-A1 | CARBAZOLE COMPOUNDS USEFUL AS BROMODOMAIN INHIBITORS | BRD3, BRD4, BRPF3 | KDM4E 975/4885APEX1 1025/4885GLA 2943/4885 |
| US-20020151558-A1 | Triazolo compounds as MMP inhibitors | MMP8, MMP13, MMP9 | KDM4E 2363/4885APEX1 3985/4885GLA 1326/4885 |
| US-20190152979-A1 | SUBSTITUTED PYRAZOLOQUINAZOLINONES AND PYRROLOQUINAZOLINONES AS ALLOSTERIC MODULATORS OF GROUP II METABOTROPIC GLUTAMATE RECEPTORS | GRM1, GRM2, GRIN1 | KDM4E 2238/4885APEX1 3723/4885GLA 4591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.